- Tags: diabetic retinopathy
Research
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.
Research
Rosacea may double risk for DR progression
Patients with rosacea and early-stage DR had more than twice the risk of progressing to proliferative disease—and a higher need for retinal intervention over 5 years.
Products
Biocon launches Eylea biosimilar to US market
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Pipeline
RegenxBio doses first patient in phase 2b/3 trial for DR
One-time gene therapy continues to move down the pipeline, with presentations on efficacy and safety data expected at ASRS.
Business
Bayer to acquire Perfuse Therapeutics, expanding ophthalmic pipeline
Deal includes the biotech’s investigational sustained-release implant currently in phase 2 clinical trials for glaucoma and diabetic retinopathy.
Events
Retina Summit 2026: DR referrals and genetic testing for ODs
AAO’s one-day meeting explored retina care’s shift from referral-based to decision-making at the OD level.
Research
Severe DR linked to higher dementia risk
Association reinforces the potential role of routine eye exams in early cognitive screening.
Research
Study: High-intensity exercise critical for reducing DR
Physical activity also improved peripheral retinal vessel measurements, with benefits peaking around five sessions and 180 minutes per week.
Pipeline
Kodiak reports positive phase 3 data on tarcocimab for DR
Topline findings from the GLOW2 trial indicate Zenkuda’s superiority over sham as company plans for a multi-indication FDA filing.
Products
Eyedaptic launches latest version of AI-based smart glasses for AMD
Designed for patients with retinal diseases, the EYE7 is an integrated wearable solution with real-time vision enhancements and a new visual assistant.
Research
Study correlates visual impairment with sleep disruptions
Poor sleep quality associated with a significantly higher risk of visual impairment, diabetic retinopathy, and other ocular conditions.
Products
AEYE Health broadens Epic EMR integration for AI eye screening
Expanded deployment enables HCPs to order AEYE-DS’s portable, 1-minute diabetic retinopathy screenings without clinical workflow disruptions.
Research
Study demonstrates accuracy of new platform for comparing AI-based DR screening systems
New testing platform allows for comparison of effectiveness and fairness in commercial AI systems.
Research
Could high HDL levels lead to lower DR risk?
Study emphasizes importance of monitoring HDL levels in patients with diabetic retinopathy.
Research
GLP-1 use may lower long-term DME, DR risk
Study highlights protective effect of GLP-1 RAs against ocular complications of diabetes and disparities for racialized patients
Products
FDA approves Formycon and Bioeq's Lucentis biosimilar
Nufymco (ranibizumab-leyk) marks the companies’ second ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Research
Does YAG capsulotomy increase DR risk?
Study highlights need for close monitoring of NPDR patients after posterior capsule opacification treatment.
Research
Could DR screenings benefit CVD detection?
Study explores potential of unexpected early advantages for patients with type 2 diabetes mellitus during routine eye exams.
Research
Clinicians are under-utilizing this AI-based DR screening system
EyeArt system demonstrates high diagnostic accuracy in detecting DR, though obstacles remain for real-world implementation.
Research